Patent details

LUC00305 Product Name: Nirsevimab

Basic Information

Publication number:
LUC00305
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP157370685
Legal Status:
Inactive
Application number:
LUC00305
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1689
Marketing Authorization Type:
Marketing Authorization Date:
03/11/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
27/04/2023
First Marketing Authorization date:
03/11/2022
Grant date:
22/09/2025
Activation date:
Publication date:
27/04/2023
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
03/11/2037
SPC Extension Expiration:
03/11/2037
Rejection date:
Withdrawal date:

Owner

From:
27/04/2023
 
 

Name:
MEDIMMUNE LIMITED
Address:
Milstein Building, Granta Park, CB21 6GH, Cambridge, , United Kingdom (GB)

Agent

Name:
ARONOVA S.A.
From:
27/04/2023
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2023/06
Publication date:
05/05/2023
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/11
Publication date:
02/10/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/01/2035
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer: